Compile Data Set for Download or QSAR
Report error Found 963 Enz. Inhib. hit(s) with all data for entry = 12820
TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730926(US20250122183, Example 139)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730902(US20250122183, Example 115)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730882(US20250122183, Example 095)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731005(US20250122183, Example 218)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730869(US20250122183, Example 082)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730964(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730848(US20250122183, Example 061)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730871(US20250122183, Example 084)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730851(US20250122183, Example 064)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730906(US20250122183, Example 119)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731006(US20250122183, Example 219)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730804(US20250122183, Example 016)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731004(US20250122183, Example 217)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730964(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731037(US20250122183, Example 250)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731003(US20250122183, Example 216)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731031(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731036(US20250122183, Example 249)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731036(US20250122183, Example 249)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731013(US20250122183, Example 226)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731052(US20250122183, Example 265)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730882(US20250122183, Example 095)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730909(US20250122183, Example 122)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730972(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730965(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731002(US20250122183, Example 215)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730821(US20250122183, Example 034)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730962(N-{6[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-meth...)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731023(US20250122183, Example 236)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730990(US20250122183, Example 203)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731007(US20250122183, Example 220)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731005(US20250122183, Example 218)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM580774(US11492346, Example 119 | US20250122183, Example 0...)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731010(US20250122183, Example 223)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730957(US20250122183, Example 170)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731014(US20250122183, Example 227)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731009(US20250122183, Example 222)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730793(US20250122183, Example 005)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730817(US20250122183, Example 030)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731000(US20250122183, Example 213)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731034(US20250122183, Example 247)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730886(US20250122183, Example 099)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730784(US20250122183, Example 003)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730956(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.5nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731019(US20250122183, Example 232)
Affinity DataKi:  0.600nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731060(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.600nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730936(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.600nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731040(US20250122183, Example 253)
Affinity DataKi:  0.600nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731012(US20250122183, Example 225)
Affinity DataKi:  0.600nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730864(US20250122183, Example 077)
Affinity DataKi:  0.600nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

Displayed 1 to 50 (of 963 total ) | Next | Last >>
Jump to: